Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Newer approaches to the treatment of rheumatoid arthritis Finesilver AGWMJ 2003[]; 102 (7): 34-7Growing evidence suggests that rheumatoid arthritis should no longer be considered a benign disease. Considerable data suggest that this disease is associated with diminished long-term survival. Other studies have also shown that in patients with rheumatoid arthritis, bone damage can occur very early in the disease course. Older disease modifying agents for treating rheumatoid arthritis were limited by long-term toxicity. Newer agents, including methotrexate, leflunomide, and the biologic agents etanercept, infliximab, adalimumab, and anakinra have shown long-term efficacy and superior long-term tolerability. Newer approaches to treating this disease have stressed treatment early in the disease course, before irreversible joint damage occurs, using combinations of second line disease modifying agents.|Adalimumab[MESH]|Antibodies, Monoclonal, Humanized[MESH]|Antibodies, Monoclonal/therapeutic use[MESH]|Antirheumatic Agents/*therapeutic use[MESH]|Arthritis, Rheumatoid/*drug therapy/epidemiology[MESH]|Drug Therapy, Combination[MESH]|Etanercept[MESH]|Humans[MESH]|Hydroxychloroquine/therapeutic use[MESH]|Immunoglobulin G/therapeutic use[MESH]|Infliximab[MESH]|Isoxazoles/therapeutic use[MESH]|Leflunomide[MESH]|Methotrexate/therapeutic use[MESH]|Prednisolone/therapeutic use[MESH]|Receptors, Tumor Necrosis Factor/therapeutic use[MESH] |